40279-93-4

Upstream product

• 98-09-9 benzenesulfonyl chloride 
• 16367-71-8 t-butyl (RS)-phenylalaninate 
• 150-30-1 Phenylalanine 

Relevant academic research and scientific papers

Spectroscopic, viscometric and computational binding study of 1 and 2 substituted anthraquinone analogs to be potential anti-cancer agents

Mitoxantrone is a well-known anthraquinone class of anti-cancer drug used against a variety of cancers. To examine the positional effect of substituent groups on the bioactivities of biologically important anthraquinone class of compounds, two analogs (1P

Structural characterization, photoluminescence, computational studies and bioassay of newly synthesized N-(3-oxo-3-morpholino-1-phenyl-propyl) benzo sulfonamide with multifunctional application

N-(3-oxo-3-morpholino-1-phenyl-propyl) benzo sulfonamide (BMS) (C19H22N2O4S) has been synthesized and characterized by FT-IR, 1H and 13C NMR, and ESI-mass spectrometric methods. The 2-D NMR

Enzyme inhibition and antioxidant potential of new synthesized sulfonamides; synthesis, single crystal and molecular docking

This study describes the synthesis of four (1-4) new phenylalanine based sulfonamides from benzene sulfonyl chlorides. The progress of the reaction was monitored on TLC and after completion; the products were subjected to various analyses that indicated t

Sulfonamide phenylalanine (SPA) series of analogues as an antibacterial, antifungal, anticancer agents along with p53 tumor suppressor-DNA complex inhibitor–part 1

A series of N-[1-benzyl-2-oxo-2-substituted(ethyl)] benzene/p-toluene sulfonamide (K1–K12) are synthesized. Structure of the synthesized analogues has been confirmed by FT-IR, 1H & 13C NMR and ESI-MS spectroscopic techniques. All the

Novel Phenoxazinones as potent agonist of PPAR-α: Design, synthesis, molecular docking and in vivo studies

Background: The use of statin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for the treatment of dyslipidemia has been associated with dose limiting hepatoxicity, mytotoxicity and tolerability due to myalgias thereby necessitating the synthesis of new drug candidates for the treatment of lipid disorder. Methods: The reaction of appropriate benzenesulphonamide with substituted phenoxazinone in the presence of phenylboronic acid gave the targeted compounds. The molecular docking study were carried out using autodock tool against peroxisome proliferator activated receptor alpha. The in vivo lipid profile were assayed using conventional methods. The kidney and liver function test were carried out to assess the effect of the derivatives on the organs. The LD50 of the most active derivatives were determined using mice. Results: The targeted compounds were successfully synthesized in excellent yields and characterized using spectroscopic techniques. The results of the molecular docking experiment showed that they were good stimulant of peroxisome proliferator activated receptor alpha. Compound 9f showed activity at Ki of 2.8 nM and binding energy of 12.6 kcal/mol. All the compounds tested reduced triglyceride, total cholesterol, low density lipoprotein cholesterol and very low density lipoprotein cholesterol level in the mice model. Some of the reported compounds also increased high density lipoprotein cholesterol level in the mice. The compounds did not have appreciable effect on the kidney and liver of the mice used. The LD50 showed that the novel compounds have improved toxicity profile. Conclusion: The synthesis of fifteen new derivatives of carboxamides bearing phenoxazinone and sulphonamide were successful. The compounds possessed comparable activity to gemfibrozil. The reported compounds had better toxicity profile than gemfibrozil and could serve as a replacement for the statins and fibrate class of lipid agents.

The use of cellulose (chromatography paper) as a cheap, versatile and non-covalent support for organic molecules during multi-step synthesis

Cellulose chromatography paper provides a novel non-covalent support for synthesis and in-situ purification of multi-dimensional arrays.

HYDRAZIDE COMPOUNDS

Compounds of formula (I):R—NH—A—CO—NH—NH—(W) n—Z (I) wherein:n is 0 or 1, W represents —CO— or S(O) r wherein r is 0, 1 or 2,Z represents a group selected from aryl, arylalkyl, heteroaryl and heteroarylalkyl, each optionally substituted,R represents a grouping selected from:Z 1—T—CO—, Z 1—O—T—CO—, Z 1—T—O—CO—, Z 1—T— S(O) q—wherein Z 1, T and q are as defined in the description,A represents alkylene, alkenylene or alkynylene each having from 3 to 8 carbon atoms, alkylenecycloalkylene, cycloalkylenealkylene, alkylenecycloalkylenealkylene, alkylenearylene, arylenealkylene, alkylenearylenealkylene a grouping whereinB 1 is as defined in the description, or A forms with the adjacent nitrogen atom a grouping as defined in the description, andmedicinal products containing the same which are useful as Neuropeptide Y receptors ligands.